title: Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs.
abstract: We reduced EAE severity by using two anti-allergic drugs. A control group of mice received i.p. injections of PBS as vehicle while a further two groups were treated either with pyrilamine, a histamine receptor 1 antagonist or with CV6209, a platelet activating factor receptor antagonist. Our results showed that the blockade of the responses to both histamine and PAF leads together to a decline in clinical signs of EAE and significant changes in the serum IgG recognition of some healthy brain antigenic targets. We characterized two discriminant antigens: internexin neuronal intermediate filament protein, and malate dehydrogenase 1, which were able to clearly distinguish untreated mice from treated mice. Their role as potent targets in pathogenic and/or neuroprotective processes is discussed.
authors.affiliation: Laboratoire d'immunologie EA2686, Faculté de Médecine, 1, Place de Verdun, 59045 Lille Cedex, France.
authors.forename: Mohamed
authors.initials: M
authors.lastname: El Behi
authors.forename: Hélène
authors.initials: H
authors.lastname: Zéphir
authors.forename: Didier
authors.initials: D
authors.lastname: Lefranc
authors.forename: Virginie
authors.initials: V
authors.lastname: Dutoit
authors.forename: Patricia
authors.initials: P
authors.lastname: Dussart
authors.forename: Patrick
authors.initials: P
authors.lastname: Devos
authors.forename: Jean Paul
authors.initials: JP
authors.lastname: Dessaint
authors.forename: Patrick
authors.initials: P
authors.lastname: Vermersch
authors.forename: Lionel
authors.initials: L
authors.lastname: Prin
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000276:immunology*; D002490:Central Nervous System / Q000276:immunology; D004586:Electrophoresis; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology*; D005260:Female; D006633:Histamine Antagonists / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000276:immunology*; D007381:Intermediate Filament Proteins / Q000276:immunology; D008291:Malate Dehydrogenase / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors; D040901:Proteomics; D011726:Pyridinium Compounds / Q000494:pharmacology; D011738:Pyrilamine / Q000494:pharmacology; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists; D007074:Immunoglobulin G; D007381:Intermediate Filament Proteins; D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D011726:Pyridinium Compounds; D043562:Receptors, G-Protein-Coupled; C046643:alpha-internexin; C039351:platelet activating factor receptor; C053321:CV 6209; D008291:Malate Dehydrogenase; D011738:Pyrilamine